

RESEARCH PAPER

Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB₁ receptorB Bosier¹, E Hermans^{2,3} and DM Lambert^{1,3}¹Unité de Chimie Pharmaceutique et de Radiopharmacie (UCL 7340), Université catholique de Louvain, Brussels, Belgium and²Laboratoire de Pharmacologie expérimentale (UCL 5410), Université catholique de Louvain, Brussels, Belgium

Background and purpose: Long-term adaptations to pharmacological stimuli frequently originate from modulation of complex intracellular signalling pathways. We previously reported that HU210 and CP55940, two CB₁ cannabinoid receptor agonists, induced opposite effects on TH expression. Herein, we characterized their influence on cAMP response element (CRE) and activator protein 1 (AP-1)-mediated regulation of gene transcription.

Experimental approach: The activity of the agonists was examined on transfected N1E-115 cells in which expression of the luciferase reporter gene was controlled by transcription promoters consisting of repeats of either CRE or AP-1 elements. In addition, the implication of classical signalling pathways was investigated using a variety of kinase inhibitors.

Key results: Consistent with the CB₁-mediated reduction of cAMP accumulation, both ligands decreased CRE-driven luciferase expression with similar potencies. HU210 also exhibited a concentration-dependent reduction of luciferase activity in cells engineered to examine AP-1-controlled transcription, whereas such response was not obtained with CP55940. Responses were all inhibited by SR141716A and were modified in *Pertussis* toxin-treated cells, suggesting agonist-selective regulations of distinct G_{i/o}-dependent mechanisms through CB₁ receptor activation. Finally, PKC inhibitors efficiently inhibited the paradoxical effect of HU210 on AP-1-mediated transcription, indicating selective regulation of PKC-dependent responses.

Conclusions and implications: Together, our results demonstrate that two cannabinoid ligands, commonly used as reference agonists acting on the same receptor with similar affinities, differentially modulate gene transcription through distinct controls of AP-1. This could reflect activation of distinct subsets of G_{i/o}-proteins, supporting the concept of functional selectivity at CB₁ receptors. *British Journal of Pharmacology* (2008) **155**, 24–33; doi:10.1038/bjp.2008.230; published online 9 June 2008

Keywords: luciferase; cannabinoid; agonist-selective trafficking of receptor signalling; transcription; CRE; AP-1; functional selectivity

Abbreviations: AC, adenylyl cyclase; AP-1, activator protein 1; CP55940, (1*R*,3*R*,4*R*)-3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexan-1-ol; CRE, cAMP response element; CREB, cAMP response element-binding protein; ERK, extracellular-signal regulated kinase; HU210, (6*R*)-*trans*-3-(1,1-dimethylheptyl)-6,7,10,10-tetrahydro-1-hydroxy-6,6-dimethyl-6*H*-dibenzo(b,d)pyran-9-methanol; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated kinase kinase; PTx, *Pertussis* toxin; SR141716A, *N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H* pyrazole-3-carboxamide hydrochloride; SR144528, *N*-((1*S*)-endo-1,3,3-trimethylbicyclo(2.2.1)heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide; TH, tyrosine hydroxylase

Introduction

Besides radioligand-binding studies, pharmacological characterization of synthetic drugs acting at G-protein-coupled receptors consists of the study of their potency and intrinsic

activity in functional assays. Considering the signalling pathways activated by these receptors, these assays are generally focused on the measure of conventional immediate and transient responses, such as production of second messengers, activation of kinases or alteration in ion equilibriums. Although these acute responses provide relevant details regarding the pharmacodynamic properties of the ligand, it is well documented that delayed or long-term modulations of cell functions contribute to the clinical outcome obtained with these ligands.

Correspondence: Professor E Hermans, Laboratoire de Pharmacologie Expérimentale, Unité de pharmacologie expérimentale, Université catholique de Louvain, Avenue Hippocrate 54, UCL FARL 5410, 1200 Brussels, Belgium.
E-mail: emmanuel.hermans@uclouvain.be

³These authors contributed equally as senior investigators to this study.
Received 4 March 2008; revised 21 April 2008; accepted 8 May 2008; published online 9 June 2008

With respect to cannabinoids that are classically documented to signal through inhibition of adenylyl cyclase (AC), several reports indicate that activation of cannabinoid receptors leads to the regulation of several DNA-binding proteins, including activator protein 1 (AP-1) (Porcella *et al.*, 1998) and cAMP response element-binding protein (CREB) (Herring *et al.*, 1998). Little is presently known regarding the nature of cannabinoid-mediated cell signals putatively involved in these delayed responses. Hence, paradoxical results were sometimes observed regarding agonist-mediated alteration of second messenger production and modulation of transcriptional activity. Thus, 2-arachidonoylglycerol was shown to enhance cell transformation and carcinogenesis through the induction of AP-1 DNA binding (Zhao *et al.*, 2005), whereas Δ^9 -tetrahydrocannabinol reduced interleukin-2 transcription through a decrease in nuclear factors binding to the AP-1 site of the interleukin-2 promoter (Condie *et al.*, 1996; Faubert and Kaminski, 2000).

Apart from inhibition of AC via a *Pertussis* toxin (PTx)-sensitive G_{i/o} protein (Pertwee, 1999; Alexander *et al.*, 2008), cannabinoid-induced accumulation of cAMP has also been reported (Glass and Felder, 1997). This response is likely to reflect a functional coupling with G_s-type G proteins, as it is preserved in recombinant (Bonhaus *et al.*, 1998; Calandra *et al.*, 1999) and native (Maneuf and Brotchie, 1997; Bash *et al.*, 2003) systems after G α_i inactivation by PTx. Even more convincing are studies showing the functional switch of CB₁ receptor coupling from G α_i to G α_s following the sequestration of G_{i/o} G-protein pool through dopamine D₂ receptor coactivation (Glass and Felder, 1997) or overexpression (Jarrahian *et al.*, 2004). In addition, both CB₁ and CB₂ receptors were reported to stimulate ERK1/2 (extracellular-signal regulated kinase) (Bouaboula *et al.*, 1995) in a G_{i/o}-dependent manner, through the G $\beta\gamma$ subunit. The complexity of the intracellular signalling associated with the CB₁ receptor extends to the activation of members of the mitogen-activated protein kinases (MAPK), including c-Jun N-terminal kinase and p38 MAPK (Rueda *et al.*, 2000) and the modulation of calcium and potassium currents (Mackie and Hille, 1992; Mackie *et al.*, 1995). In addition, CB₁ receptors may induce rapid and transient elevations of intracellular free Ca²⁺ concentrations through G $\beta\gamma$ -mediated activation of PLC β (Sugiura *et al.*, 1997). Finally, regulation of PLC by CB₁ receptors was proposed to require coupling with different α -subunits of the G_{q/11} family (Ho *et al.*, 1999). Hence, the selective coupling to G_{q/11} protein in an agonist-specific manner was more recently demonstrated (Lauckner *et al.*, 2005; McIntosh *et al.*, 2007).

We recently reported cannabinoid-mediated regulation of tyrosine hydroxylase (TH) expression in the N1E-115 neuroblastoma cell line constitutively and selectively expressing the CB₁ receptor subtype. Particularly, different classes of full CB₁ agonists, belonging to different chemical families, were shown to induce opposite effects (Bosier *et al.*, 2007), raising the question of functional selectivity at the CB₁ receptor. In this context, the present study aims at further investigating CB₁ receptor-mediated signalling pathways involved in the regulation of gene expression. In view of the essential roles of both CRE and AP-1 *cis*-enhancer elements in constitutive and induced TH gene expression,

CRE- or AP-1-driven luciferase reporter gene assays were carried out to elucidate the CB₁ receptor-mediated, agonist selective regulation of signalling pathways involved in long-term control of gene transcription.

Methods

Cell culture

All cell culture media and supplements were obtained from Invitrogen (Merelbeke, Belgium). Mouse neuroblastoma N1E-115 cells were grown in Dulbecco's MEM/NUT mix F-12 medium supplemented with 10% foetal calf serum, 100 UI mL⁻¹ penicillin, 100 μ g mL⁻¹ streptomycin and 2 mM L-glutamine. All drug treatments were conducted in the same culture medium. At confluence, cells were trypsinized for dilutions. Cells were cultured at 37 °C in an atmosphere of humidified air and 5% CO₂.

cAMP assay

N1E-115 cells were seeded in 96-well plates (10⁴ cells per well), 24 h before cannabinoid treatments. Cells were pretreated for 30 min with 0.1 mM IBMX (3-isobutyl-1-methylxanthine). Then, cannabinoid agonists were added for another 30 min incubation treatment in the absence or presence of 1 μ M forskolin. When *N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H* pyrazole-3-carboxamide hydrochloride (SR141716A) and *N*-((1*S*)-endo-1,3,3-trimethylbicyclo(2.2.1)heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528) were used, cells were pretreated for 5 min with the cannabinoid inverse agonists/antagonists at 1 μ M before the addition of the cannabinoid agonist. Where indicated, cells were treated overnight with 100 ng mL⁻¹ PTx. cAMP levels were measured using cAMP Biotrak enzyme immunoassay system (Amersham Pharmacia Biotech, Roosendaal, The Netherlands), according to the protocol provided by the manufacturer. Cells were incubated at 37 °C.

Plasmids, transfection and dual luciferase assay

pCRE-Luc and pAP-1-Luc plasmids were purchased from Stratagene (La Jolla, CA, USA) and included 4 and 7 copies of CRE and AP-1 *cis*-enhancer elements, respectively, fused to the firefly luciferase gene. pRL 138 obtained from Dr E Pierreux (UCL, ICP, Brussels, Belgium) was used as an internal control to normalize for transfection variability. pRL 138 was constructed by the introduction of a 225 bp sequence of the PFK-2 promoter in the pRL null vector from Promega (Mannheim, Germany) encoding for *Renilla* luciferase, as described previously (Pierreux *et al.*, 1998).

Cells were plated at a density of 10⁵ cells per well in 24-well plates. Culture medium was changed after 24 h, and the cells were co-transfected with a reporter plasmid (3 μ g per well and 5 μ g per well for pCRE-Luc and pAP-1-Luc, respectively) and the pRL 138 plasmid at 0.25 μ g per well. Transfection was performed overnight using the calcium phosphate co-precipitation method. After transfection, cells were washed three times with PBS buffer (137 mM NaCl,

2.7 mM KCl, 8.1 mM Na₂HPO₄, 1.47 mM KH₂PO₄, pH 7.4) and fresh medium was added 24 h before the 5 h treatment with the appropriate amounts of cannabinoid agonists. When indicated, SR141716A and SR144528 were added 5 min before applying the agonist. When PTx was used, cells were treated overnight with a 100 ng mL⁻¹ concentration. To stop the reaction, cells were washed three times with PBS buffer before lysis by addition of 100 µL passive lysis buffer supplied with the Dual Luciferase Reporter Assay System (Promega). Firefly luciferase reporter activity was normalized for *Renilla* luciferase activity. Respective measurement of light emission was determined according to the manufacturer's instructions. Luminescence was detected by a TD20/20 luminometer (Turner design, Sunnyvale, CA, USA).

Data analysis and statistical procedures

Data presented in the text and in the figures were expressed as percentages of the corresponding values obtained with cells treated with vehicle (dimethyl sulphoxide diluted in culture medium). pEC₅₀ values were determined from at least three separate experiments by nonlinear regression analysis performed using Graph Pad prism software (San Diego, CA, USA). Statistical analysis was performed on the log-transformed value of relative luminescence or on the net cAMP level by ANOVA with repeated measurements or Student's *t*-test. A *post hoc* analysis was performed by Scheffe test, using the SPSS software.

Drugs, chemical reagents and other materials

(6*R*)-*trans*-3-(1,1-dimethylheptyl)-6,7,10,10-tetrahydro-1-hydroxy-6,6-dimethyl-6*H*-dibenzo(b,d)pyran-9-methanol (HU210) and (1*R*,3*R*,4*R*)-3-(2-hydroxy-4-(1,1-dimethylheptyl) phenyl)-4-(3-hydroxypropyl)cyclohexan-1-ol (CP55940) were purchased from Tocris Cookson (Bristol, UK). The CB₁ receptor inverse agonist/antagonist, SR141716A, and the CB₂ receptor inverse agonist/antagonist, SR144528, were generously provided by Dr Barth and Dr Mossé, respectively (Sanofi-Synthélabo Research, Montpellier, France). Forskolin, IBMX, phorbol 12-myristate 13-acetate and PTx were purchased from Sigma (Boornem, Belgium). Stock solutions of drugs were prepared in dimethyl sulphoxide at 0.01 M and stored in aliquots at -80 °C. The final dimethyl sulphoxide concentration never exceeded 0.1%, which had no significant effect on assays.

Results

Modulation of cAMP accumulation

In agreement with several studies indicating the functional coupling of the cannabinoid receptors with G_{i/o} proteins, both HU210 (0.1 µM) and CP55940 (0.1 µM), two typical cannabinoid full agonists, elicited a significant reduction in cAMP accumulation in N1E-115 neuroblastoma cells (21.8 and 36.5% reduction relative to control cells, respectively) (Figure 1a). To facilitate the detection of G_{i/o}-mediated responses, basal AC activity was enhanced by the addition of 1 µM forskolin (leading to a robust 725 ± 56% induction of




Figure 1 Regulation of cAMP accumulation in N1E-115 neuroblastoma cells. Cells were exposed to HU210 or CP55940 (0.1 µM), in the absence (a) or presence (b) of 1 µM forskolin. The responses to both agonists were also measured after overnight treatment of the cells with PTx (100 ng mL⁻¹). Results are expressed as percentage of responses in control cells (exposed to vehicle or forskolin, which caused a sevenfold increase in basal cAMP accumulation). Data are mean values with s.e.mean from three separate experiments performed in triplicate. ***P* < 0.01, **P* < 0.05 relative to control condition; ##*P* < 0.01, #*P* < 0.05 relative to responses in the presence of PTx.

cAMP accumulation, relative to control). At the tested concentration, maximal response to forskolin is certainly not reached, as the EC₅₀ value of forskolin in mediating cAMP accumulation in N1E-115 cells is close to 10 µM (Stenstrom *et al.*, 1985; Murphy and Byczko, 1989). In these conditions, both HU210 and CP55940 exhibited a more pronounced inhibition of cAMP formation (50.9 and 56.0% reduction relative to forskolin treated cells, respectively) (Figure 1b). Confirming the specific involvement of CB₁ receptors, these responses were totally prevented by SR141716A, a selective CB₁ inverse agonist/antagonist, whereas SR144528, a selective CB₂ inverse agonist/antagonist, had no influence on the agonist-mediated reduction of cAMP levels (data not shown). Although basal cAMP level was significantly decreased in PTx-treated cells, HU210 (0.1 µM) and CP55940 (0.1 µM) elicited a significant increase in cAMP synthesis either in the absence (30.0 and 28.4%, respectively) or presence of forskolin (32.0 and 18.4%, respectively) (Figure 1). Increased cAMP level induced by cannabinoids was already reported, when tested in the

absence of functional G_{i/o} proteins, and is currently attributed to a functional coupling of the CB₁ receptor with G_s proteins.

Cannabinoid-mediated regulation of CRE and AP-1-dependent transcriptional activity

To examine the effects of CB₁ receptor activation on CRE and AP-1-dependent transcriptional activities, N1E-115 cells were transiently transfected with plasmid constructs containing the luciferase gene under the control of *cis*-enhancer element repeats of either CRE (pCRE-Luc) or AP-1 (pAP-1-Luc). As expected, cells transfected with pCRE-Luc constructs displayed a robust basal luciferase activity (not shown), confirming a constitutive activity of CRE-dependent transcription in N1E-115 cells. In addition, the strong increase in luciferase activity (up to 850%) observed with forskolin 1 μ M confirmed that the luciferase reporter gene is a reliable indicator of cAMP levels in this model. Both HU210 and CP55940 were found to modestly inhibit CRE-mediated transcriptional activity (estimated pEC₅₀ values of 7.21 \pm 0.01 and 6.82 \pm 0.09, respectively) (Figure 2a). More convincingly, when the agonists were tested in cells exposed to forskolin, both markedly reduced luciferase expression in a concentration-dependent manner, with pEC₅₀ values of 7.60 \pm 0.01 and 8.07 \pm 0.04 for HU210 and CP55940, respectively. In this assay, the analysis of concentration–response curves indicated Hill slopes distinct from unity (0.47 \pm 0.04 and 0.41 \pm 0.02 for HU210 and CP55940, respectively). Nevertheless, the responses to both agonists were markedly impaired using SR141716A (Figure 2b), suggesting that inhibition of CRE activity was specifically driven through CB₁ receptor-dependent signalling pathways.

Experiments were repeated in cells engineered to examine AP-1-controlled luciferase activity. As with the CRE construct, a noticeable constitutive AP-1-driven luciferase activity was detected. The efficiency of this system was validated using 0.08 μ M phorbol 12-myristate 13-acetate, a PKC activator known to regulate AP-1 transcription, which produced a modest but significant increase in luciferase activity (124.8 \pm 2.4%, relative to control; P < 0.01). In this assay, HU210 elicited a concentration-dependent reduction of AP-1 activity (pEC₅₀ of 7.95 \pm 0.11) (Figure 3a) and experimental data best fitted with a standard sigmoidal curve (Hill slope close to 1). Again, SR141716A abolished the HU210-mediated response (Figure 3b), confirming that the regulation of AP-1-dependent transcription was operating through CB₁ receptor activation.

Surprisingly, no significant influence on AP-1 activity was observed using CP55940, indicating that this commonly used agonist of the CB₁ receptor behaves as a neutral ligand on the cell-signalling pathway regulating AP-1-dependent transcriptional activity. The pharmacological profile of CP55940 was further examined by analysing its ability to antagonize cannabinoid-mediated regulation of AP-1 activity. As shown in Figure 4, CP55940 caused a concentration-dependent rightward shift of the sigmoidal curve for HU210-induced luciferase activation. This clearly identifies CP55940 as a competitive antagonist at the CB₁ receptor in this




Figure 2 Cannabinoid-mediated regulation of CRE-dependent transcriptional activity in N1E-115 neuroblastoma cells. Luciferase activity was measured in transiently transfected N1E-115 cells carrying the pCRE-Luc construct. Cells were exposed to increasing concentrations of HU210 or CP55940 in the absence or presence of 1 μ M forskolin (a) and luciferase activity was monitored 5 h later. The responses to both agonists (used at 0.1 μ M) were also measured in the presence of 1 μ M SR141716A (b). The role of G_{i/o}-type G proteins was investigated by repeating these measures in the presence of forskolin on cells treated overnight with PTx (100 ng mL⁻¹) (c). Results (mean values with s.e.mean from at least three separate experiments performed in triplicate) are given as the percentages of relative luciferase activity (firefly luciferase relative to *Renilla* luciferase activity) compared with untreated or forskolin-treated cells. Forskolin increased the basal level of luciferase by 8.5-fold. ** P < 0.01 and * P < 0.05 denote significant difference as compared with control conditions.

functional assay and Schild plot transformation indicated a pA₂ value of 8.48 (95% confidence interval of 8.22–8.92).

Signalling pathways involved in CRE and AP-1-dependent transcriptional activity

The cellular mechanisms involved in the regulation of CRE and AP-1-dependent transcriptional activity by cannabinoid agonists were examined using inhibitors of intracellular signalling cascades putatively associated with CB₁ receptor functions. As this receptor appears predominantly associated with modulation of cAMP levels, we first studied the effect of the PKA inhibitors, H89 and KT5720, on both CRE and




Figure 3 HU210-mediated regulation of AP-1-dependent transcriptional activity in N1E-115 neuroblastoma cells. Luciferase activity was measured in N1E-115 cells transiently transfected with pAP-1-Luc construct. (a) Cells were exposed to increasing concentrations of HU210 or CP55940 and luciferase activity was monitored 5 h later. The responses to both agonists (used at 0.1 μ M) were also measured in the presence of 1 μ M SR141716A (b). Results shown are mean values with s.e.mean from at least three separate experiments performed in triplicate and are given as the percentages of relative luciferase activity (firefly luciferase relative to *Renilla* luciferase activity) compared with untreated cells. ** $P < 0.01$ and * $P < 0.05$ denote significant difference as compared with control conditions.

AP-1-driven luciferase activities. Also, as cannabinoid responses on CRE activity were more pronounced when the basal activity of AC was boosted, the effect of inhibitors on CRE-controlled transcription was evaluated in the presence of 1 μ M forskolin. As expected, incubation of N1E-115 cells with H89 (10 μ M) or KT5720 (5 μ M) significantly reduced pCRE-Luc activity in the presence of forskolin (Table 1). In the same conditions, these PKA inhibitors completely abolished the modulation of pCRE-Luc activity caused by the cannabinoid agonists HU210 and CP55940.

The effects of MAPK kinase (MEK) and PI3K inhibitors were also investigated, as cannabinoids are known to regulate MAPK activity, possibly through PI3K activation. The MEK inhibitors U0126 (5 μ M) and PD98059 (25 μ M) were found to decrease the effect of forskolin on CRE-driven luciferase




Figure 4 CP55940 competitively antagonizes HU210-induced inhibition of AP-1-dependent luciferase activity. Luciferase activity was measured in N1E-115 cells transiently transfected with pAP-1-Luc construct. The apparent potency of HU210 in decreasing luciferase activity was evaluated in the presence of different concentrations of CP55940. Inset: Schild plot analysis allowing estimation of the pA_2 value of CP55940 at inhibiting the response to HU210. Results shown are mean values with s.e.mean from at least three separate experiments performed in triplicate and are given as the percentage of relative luciferase activity (firefly luciferase relative to *Renilla* luciferase activity) as compared with untreated cells.

Table 1 Biochemical characterization of the signalling pathways involved in the modulation of pCRE-Luc activity by cannabinoid ligands

Treatments	No agonist	HU210	CP55940
No inhibitor	100.0 \pm 0.2	75.0 \pm 0.9**	65.7 \pm 2.3**
<i>PKA inhibitors</i>			
H89 (10 μ M)	45.7 \pm 7.2*	48.9 \pm 9.3	52.1 \pm 10.2
KT5720 (5 μ M)	100.0 \pm 15	106.4 \pm 8.5	112.2 \pm 21.1
	62.9 \pm 1.8*	67.7 \pm 5.5	65.5 \pm 2.7
	100.0 \pm 2.9	107.9 \pm 12.1	102.6 \pm 7.2
<i>MEK/MAPKK inhibitors</i>			
U0126 (5 μ M)	83.6 \pm 4.1*	64.7 \pm 7.2	62.1 \pm 7.1
	100.0 \pm 4.9	76.6 \pm 4.8 [#]	74.1 \pm 6.7 [#]
PD98059 (25 μ M)	78.2 \pm 4.3**	61.7 \pm 6.9	56.0 \pm 5.3
	100.0 \pm 5.5	78.6 \pm 4.4 [#]	71.4 \pm 2.8 [#]
<i>PI3K inhibitor</i>			
Wortmannin (0.2 μ M)	114.3 \pm 5.4	85.9 \pm 1.8	70.7 \pm 6.5
	100.0 \pm 4.7	74.9 \pm 2.8 ^{###}	61.9 \pm 5.1 ^{###}
<i>PKC inhibitors</i>			
Chelerythrine (10 μ M)	101.8 \pm 3.7	73.2 \pm 1.9	67.9 \pm 4.7
	100.0 \pm 3.7	75.4 \pm 2.1 ^{###}	68.7 \pm 2.1 ^{###}
GF109203X (0.25 μ M)	124.7 \pm 12.1	108.2 \pm 11.0	79.7 \pm 3.2
	100.0 \pm 9.7	80.6 \pm 2.4 [#]	65.0 \pm 3.3 ^{###}

Transfected N1E-115 cells carrying pCRE-Luc construct were pretreated for 1 h in the absence or presence of inhibitors. Thereafter, cells were exposed to a vehicle, HU210 (0.1 μ M) or CP55940 (0.1 μ M), in the presence of forskolin 1 μ M, and the luciferase activity was monitored 5 h later. Results are given as the percentages of luciferase activity compared with control (forskolin only). Numbers in italics show the same data normalized to the values obtained in the presence of the inhibitor (set at 100%). Shown are mean values with s.e.mean from at least three independent experiments performed in triplicate. ** $P < 0.01$, * $P < 0.05$ relative to forskolin-induced response; ^{###} $P < 0.01$, [#] $P < 0.05$ relative to the cells treated with the inhibitor alone.

transcription. Similar reduction in CRE activity was observed in the absence of forskolin (74.5 \pm 7.9 and 67.1 \pm 2.3% relative to control cells, for U0126 and PD98059,

Table 2 Biochemical characterization of the signalling pathways involved in the modulation of pAP-1-Luc activity by cannabinoid ligands

Treatments	No agonist	HU210	CP55940
No inhibitor	100.0 ± 0.76	65.3 ± 5.8**	101.1 ± 4.4
<i>PKA inhibitors</i>			
H89 (10 µM)	98.5 ± 11.2 <i>100.0 ± 11.1</i>	71.5 ± 6.5 <i>73.0 ± 2.2#</i>	104.8 ± 7.1 <i>105.6 ± 6.0</i>
KT5720 (5 µM)	94.3 ± 1.0 <i>100.0 ± 1.1</i>	70.1 ± 2.3 <i>74.3 ± 3.1##</i>	96.9 ± 2.5 <i>101.4 ± 2.4</i>
<i>MEK/MAPKK inhibitors</i>			
U0126 (5 µM)	94.9 ± 12 <i>100.0 ± 13.0</i>	58.1 ± 9.2 <i>60.7 ± 2.7#</i>	104.6 ± 9.6 <i>107.3 ± 7.4</i>
PD98059 (25 µM)	74.3 ± 1.0** <i>100.0 ± 1.3</i>	52.8 ± 1.5 <i>71.0 ± 3.0##</i>	74.3 ± 1.8 <i>100.1 ± 3.9</i>
<i>PI3K inhibitor</i>			
Wortmannin (0.2 µM)	300.4 ± 68.1* <i>100.0 ± 22.2</i>	212.7 ± 58.3 <i>68.7 ± 5.0</i>	315.9 ± 38.3 <i>107.4 ± 5.5</i>
<i>PKC inhibitors</i>			
Chelerythrine (10 µM)	70.1 ± 2.8** <i>100.0 ± 3.9</i>	70.9 ± 4.9 <i>101.1 ± 3.1</i>	72.8 ± 6.9 <i>103.6 ± 5.8</i>
GF109203X (0.25 µM)	65.6 ± 11.0** <i>100.0 ± 16.1</i>	75.3 ± 25.0 <i>108.7 ± 17.1</i>	73.6 ± 19.1 <i>113.4 ± 8.6</i>
<i>Negative control for PKC inhibition</i>			
Ro-31-6045 (0.25 µM)	100.0 ± 1.5 <i>100.0 ± 1.5</i>	61.2 ± 1.6 <i>61.2 ± 1.6##</i>	98.9 ± 0.4 <i>98.9 ± 0.4</i>

MEK, mitogen-activated kinase kinase; MAPK, mitogen-activated protein kinase.

Transfected N1E-115 cells carrying pAP-1-Luc construct were pretreated for 1 h in the absence or presence of inhibitors. Thereafter, cells were exposed to a vehicle, HU210 (0.1 µM) or CP55940 (0.1 µM), and the luciferase activity was monitored 5 h later. Results are given as the percentages of luciferase activity compared with control. Numbers in italics show the same data normalized to the values obtained in the presence of the inhibitor (set at 100%). Shown are mean values with s.e.mean from at least three independent experiments performed in triplicate.

** $P < 0.01$, * $P < 0.05$ relative to control; ## $P < 0.01$, # $P < 0.05$ relative to the cells treated with the inhibitor alone.

respectively), suggesting that MAPKs are involved in the basal activity of CRE *cis*-enhancer elements. In contrast, these MEK inhibitors as well as the PI3K inhibitor wortmannin (0.2 µM) failed to reduce the effects of HU210 or CP55940. Finally, the PKC inhibitors chelerythrine (10 µM) or GF 109203X (0.25 µM), which were tested on the basis of the key role of this kinase in the modulation of AP-1-dependent transcriptional activity, were unable to influence the regulation of CRE activity by the cannabinoid agonists.

In contrast to the responses obtained with the pCRE-Luc construct, the PKA inhibitors were without influence on the HU210-mediated regulation of AP-1-driven luciferase expression, whereas efficient blockade was obtained with the PKC inhibitors (Table 2). Compound Ro-31-6045, an analogue of GF 109203X, generally used as a negative control for inhibition of PKC activity, failed to influence the response to HU210, validating the specificity of the PKC inhibition. The failure of CP55940 to efficiently regulate AP-1 element was confirmed by our finding that none of the inhibitors tested here affected the response to this agonist. When used alone, inhibitors of MEK, PI3K or PKC were also found to affect the basal AP-1-mediated luciferase activity, suggesting

that these kinases are involved in the constitutive AP-1-dependent transcriptional activity. Finally, neither MEK nor PI3K inhibitors appeared to influence the response to HU210.

Cannabinoid-mediated regulation of CRE and AP-1-dependent transcriptional activity is directed by G_{i/o} proteins

The role of G_{i/o}-type G proteins in the modulation of gene transcription by cannabinoid agonists was examined by repeating the luciferase reporter assays in cells treated overnight with PTx (100 ng mL⁻¹). In cells expressing either the pCRE-Luc or pAP-1-Luc constructs, the basal luciferase activities appeared to be substantially increased after treatment with PTx (17.4 and 12.4% relative to control, respectively), indicating that both transcription promoters were negatively influenced by a constitutive activation of G_{i/o}-type G proteins.

As shown in Figure 2c, the inhibition of CRE-dependent luciferase activity induced by both HU210 and CP55940 in the presence of forskolin was abolished by PTx pretreatment (Figure 2c). In contrast, when the assay was conducted in the absence of forskolin, the effect of cannabinoid agonists was switched from inhibition to induction of CRE-dependent transcription, and concentration–response curves revealed pEC₅₀ values of 6.64 ± 0.26 and 6.67 ± 0.27 for HU210 and CP55940, respectively (Figure 5a). These data are consistent with the above-mentioned increase in cAMP levels in PTx-treated cells, demonstrating the dual coupling of the CB₁ receptor with the G_{i/o} and G_s-type G proteins.

Such reversal of the functional response to HU210 in PTx-treated cells was also observed when studying the modulation of luciferase under the control of AP-1. In these conditions, HU210 concentration-dependently stimulated luciferase activity with pEC₅₀ values of 7.66 ± 0.38. More surprisingly, in this model of PTx-treated cells, CP55940 appeared to be effective in inducing AP-1-dependent transcription with a pEC₅₀ of 6.48 ± 0.23 (Figure 5b). Together, these data indicate that the regulation of AP-1 activity by cannabinoid agonists was also operating through the activation of members of the G_{i/o} protein family.

Discussion and conclusions

The effects of cannabinoids on CNS activity are frequently related to the CB₁ receptor-mediated regulation of signalling cascades, controlling the release of other neurotransmitters. Beside these acute responses, several reports indicate that activation of the CB₁ receptor modulates transcription factors, including CREB, nuclear factor kappa B, nuclear factor-activated T cells and AP-1 (Ouyang *et al.*, 1998; Herring *et al.*, 2001). In this study, using N1E-115 neuroblastoma cells that constitutively express CB₁ receptors, we report that the cannabinoid agonist HU210 concentration-dependently inhibits both CRE and AP-1-mediated transcriptional activities. In contrast, the unrelated cannabinoid agonist CP55940 fails to influence AP-1-controlled gene expression while efficiently regulating CRE activity. Furthermore, these responses are abolished and/or reversed in the




Figure 5 Involvement of $G_{i/o}$ -type G proteins in the modulation of CRE and AP-1-dependent transcriptional activities by cannabinoid ligands. Luciferase activity was measured in N1E-115 cells transiently transfected with either pCRE (a) or pAP-1-Luc (b) constructs. Cells were treated overnight with 100 ng mL^{-1} PTx. Thereafter, cells were exposed to increasing concentrations of HU210 or CP55940 and luciferase activity was monitored after 5 h. Results shown are mean values with s.e.mean from at least three separate experiments performed in triplicate and are given as the percentage of relative luciferase activity (firefly luciferase relative to *Renilla* luciferase activity) compared with control. * $P < 0.05$ denotes significant difference as compared with control conditions.

cells treated with PTx, suggesting the involvement of $G_{i/o}$ -type G proteins.

Although the involvement of cannabinoid receptors was not definitely established, cAMP-dependent inhibition of CREB DNA binding after cannabinoid treatment has been previously demonstrated (Koh *et al.*, 1997; Herring *et al.*, 1998, 2001). More recently, CB₁ receptor-mediated increase in CREB activation through ERK-dependent signalling was demonstrated in discrete regions of the rat brain after administration of cannabinoid agonists (Casu *et al.*, 2005; Rubino *et al.*, 2007). Consistent with these studies, the use of a specific luciferase-based reporter assay revealed that both HU210 and CP55940 concentration-dependently inhibited CRE-dependent transcriptional activity through activation of CB₁ receptors, as indicated by the efficient blockade of the responses by SR141716A. The detection of this response was facilitated in cells exposed to forskolin, which boosts basal CRE-dependent transcriptional activity, suggesting that agonists were acting through inhibition of AC. This is consistent with our data showing a decreased cAMP

accumulation in cells exposed to HU210 and CP55940. Indeed, the use of specific inhibitors confirmed that PKA was required for the forskolin-mediated induction of basal CRE activity. Accordingly, the PKA inhibitors totally abolished HU210 and CP55940-mediated regulation of CRE-dependent luciferase activity. Together, these data strongly support the general concept that agonists of CB₁ receptors influence gene transcription through inhibition of cAMP production and modulation of PKA activity. Nevertheless, concentration–response curves were characterized by a Hill coefficient < 1 , indicating that the regulation of CRE-dependent activity by the cannabinoid agonists could involve the combination of distinct but converging signalling pathways. Although cannabinoid receptors have been shown to regulate several types of G proteins, this complexity could merely involve different members of the family of $G_{i/o}$ proteins.

The AP-1 transcription factor is best characterized as a family of protein heterodimers encoded by defined immediate early genes, such as c-Fos and JunB. Therefore, AP-1 activity is dependent on the level of immediate early gene expression and the phosphorylation of the different subunits by PKC, ERK or c-Jun N-terminal kinase. As cannabinoid receptors are known to activate ERK1/2 and c-Jun N-terminal kinase, and regulate the expression of immediate early genes, the effects of cannabinoid agonists on AP-1-dependent transcriptional activity were characterized. Several studies have already shown cannabinoid-mediated regulations of AP-1 activity with inconsistent responses reflecting either increased or decreased in AP-1 DNA binding and/or AP-1-controlled transcription (Porcella *et al.*, 1998; Faubert and Kaminski, 2000; Zhao *et al.*, 2005; Giuliano *et al.*, 2006). Here, the direct measure of AP-1-dependent activity revealed a reduction of AP-1-mediated transcription in neuroblastoma cells, consecutively to HU210 stimulation. Accordingly, anandamide-mediated inhibition of AP-1 activation in a CB₁ receptor- and PKC-dependent mechanism was previously demonstrated (Maccarrone *et al.*, 2003). Likewise, HU210-mediated inhibition of AP-1-driven luciferase activity was efficiently inhibited by PKC inhibitors and antagonized using SR141716A. Although regulation of PKC-related pathways by cannabinoids remains poorly documented, several studies have already suggested a role of this kinase in cannabinoid receptor-mediated reduction of potassium currents (Hampson *et al.*, 2000) and regulation of L-type voltage dependent calcium channels (Rubovitch *et al.*, 2002). In addition, demonstrations that CB₁ receptors may functionally interact with $G_{q/11}$ -type G protein in response to (*R*)-(+)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)-1-naphthalenylmethanone mesylate (WIN55212-2) (Lauckner *et al.*, 2005) and efficiently regulate PLC activity (Sugiura *et al.*, 1996, 1997; Ho *et al.*, 1999) are compelling indications for a CB₁ receptor-mediated regulation of PKC.

The absence of CP55940-mediated regulation of AP-1-dependent transcription clearly shows that distinct signalling cascades contribute to the modulation of CRE- and AP-1-dependent activities. In addition, these data support the concept of functional selectivity of agonists acting at the CB₁ receptor. Indeed, functional selectivity of receptor signalling is characterized by the ability of distinct ligands

acting at a single G-protein-coupled receptor to differentially control intracellular signal transduction pathways. Thus, functionally selective ligands activate or inhibit multiple intracellular cascades with different efficacies or potencies (Bosier and Hermans, 2007). Such selectivity at the level of regulation of AP-1-dependent transcriptional activity by cannabinoid agonists is an unprecedented observation. Although the expression of the CB₁ receptor in this model of neuroblastoma cells remains poorly characterized, we have accumulated convincing pharmacological data showing that both agonists tested act on a single molecular target identified as the CB₁ receptor. It is noteworthy that both agonists promote reduction of CRE-dependent luciferase activity with similar potencies and decrease cAMP. This is also consistent with the data showing the possibility to competitively antagonize the HU210-mediated regulation of AP-1-dependent response by CP55940. Importantly, the pA₂ value determined for CP55940 in this competition assay is consistent with its published nanomolar affinity for the CB₁ receptor. The detection of signalling specificity with some drugs, as shown here for CP55940, could be purely related to their partial agonist profile. For these drugs, the density of receptors and the availability of defined signalling partners could influence the apparent efficacy in functional assays. However, to our knowledge, the vast majority of pharmacological studies have identified CP55940 as a full agonist of the CB₁ receptor. In spite of repeated attempts, we failed to find cannabinoid agonist-induced [³⁵S]-GTPγS binding to G proteins in this model of neuroblastoma cells, suggesting that the expression of the CB₁ receptor is not sufficient to allow the detection of significant responses. Therefore, we were unable to characterize the potencies and efficacies of CP55940 and HU210 at the earliest steps of the signalling cascade in this model. Nevertheless, in our hands, both ligands were characterized as full agonists of the CB₁ receptor in [³⁵S]-GTPγS-binding assays conducted on mouse cerebellar membrane preparations (pEC₅₀: 7.77 ± 0.72 and 7.80 ± 0.18; E_{max}: 173 ± 1 and 176 ± 2% stimulation over basal, for HU210 and CP55940, respectively; Bosier *et al.*, unpublished data).

Although functional selectivity at G-protein-coupled receptors is extensively documented in the literature, little is known regarding the CB₁ receptor, and most available studies have been focused on coupling with different members of the G_{i/o} protein family (Glass and Northup, 1999; Prather *et al.*, 2000; Mukhopadhyay and Howlett, 2005). Nevertheless, the ability of different CB₁ receptor agonists to differentially activate G_{i/o} or G_s-dependent signalling pathways was described in recombinant systems (Bonhaus *et al.*, 1998). To our knowledge, this study provides the first evidence for functional selectivity at the native CB₁ receptor in a neural cell line, reflected by an agonist-selective response monitored at the transcriptional level. In a closely related study conducted in the same cell line, we recently reported the complex regulation of TH by CB₁ receptor agonists (Bosier *et al.*, 2007). Importantly, HU210 or CP55940 was shown to decrease or increase the expression of TH, respectively, raising the question of an agonist-selective trafficking of CB₁ receptor signalling. Earlier studies demonstrated that AP-1 and CRE motifs present in the rat TH

gene promoter were involved in the pharmacological modulation of transcription (Kim *et al.*, 1993; Najimi *et al.*, 2002; Lewis-Tuffin *et al.*, 2004). Therefore, identifying an agonist-dependent differential regulation of TH expression in a catecholamine-producing cell line, highlights the putative relevance of functional selectivity.

Inhibition or reversal of the responses to the cannabinoid agonists in PTx-treated cells suggests that both CRE and AP-1 activities are regulated through activation of G_{i/o}-type G proteins, in accordance with the documented predominant coupling of the CB₁ receptor. The unexpected reduction of basal cAMP level observed after overnight treatment with PTx could reveal some influence of this toxin on the metabolism or proliferation of N1E-115 cells. However, forskolin was found to induce equivalent increases in cAMP accumulation in cells with or without exposure to PTx (725.08 ± 55.97 and 728.58 ± 41.15% stimulation, relative to control), suggesting that the pharmacological modulation of AC and associated signalling were not affected. Taking advantage of an internal control plasmid (encoding for




Figure 6 Putative signalling pathways associated with regulation of CRE and AP-1-controlled transcription by the CB₁ receptor. Through stabilization of different active conformations of the receptor, HU210 and CP55940 could selectively promote coupling with several types of G proteins, supporting activation/inhibition of distinct signalling pathways. On the one hand, the high affinity agonists HU210 (striped arrow) and CP55940 (open arrow) mediate inhibition of CRE-dependent transcription through activation of *Pertussis* toxin-insensitive G proteins and related inhibition of AC and PKA activity, as confirmed by the use of PKA inhibitors. On the other hand, only HU210 regulates AP-1-dependent transcription via an unresolved mechanism involving the activity of PKC, as suggested by the use of appropriate inhibitors. In addition, experimental observations demonstrate the possible interaction of CB₁ receptors with PTx-insensitive G proteins. Although these alternative couplings exert a modest influence with comparison to the response mediated by G_{i/o} proteins, activation of PTx-insensitive G proteins by both HU210 and CP55940 is thought to equally promote CRE and AP-1-controlled transcription.

Renilla luciferase) that allowed us to normalize for cell density, an enhanced basal luciferase activity in PTx-treated cells was detected, confirming the stimulation of both CRE and AP-1-dependent transcription by some constitutive activation of G_{i/o}-type G proteins in N1E-115 cells. In addition, the inverse agonist, SR141716A, also increased luciferase activity (not shown), indicating that a constitutive coupling of the CB₁ receptor participates in the activation of CRE and AP-1 in the absence of agonist.

The putative interaction of the CB₁ receptor with several isoforms of G_{i/o} proteins could certainly hold clues for the diversity in intracellular signalling triggered by cannabinoid ligands and explain the results observed with HU210 and CP55940 (Figure 6). On the other hand, although the aim of the study was not to examine the diversity of couplings with different types of G proteins, our data suggest that in the absence of functional G_{i/o} protein, the CB₁ receptor may operate atypical coupling with other G proteins. Indeed, increased cAMP accumulation and stimulation of CRE-driven luciferase activity in PTx-treated cells indicate that CB₁ receptors also exert a positive influence on AC through a putative coupling with G_s-type G protein. Besides, considering the consequence of PTx pretreatment on HU210 and CP55940-mediated regulation of AP-1 activity, the possibility of coupling with members of the G_{q/11} proteins family cannot be excluded.

In conclusion, the present results indicate that two cannabinoid ligands, commonly used as reference agonists at the CB₁ receptor, may differentially influence gene transcription through distinct controls on AP-1 *cis*-enhancer DNA element. Supporting the concept of functional selectivity, these data suggest that the choice of appropriate ligands acting on a given receptor should help to selectively modulate defined cellular responses. In addition, the present observations clearly indicate that ligands, with similar pharmacodynamic properties and eliciting similar regulation of classical immediate effectors, may trigger divergent delayed responses. This should encourage the systematic study of a wide variety of early and late responses to drugs to better define their therapeutic potential or explain the differences in their clinical profiles.

Acknowledgements

This study was supported by grants from the National Fund for Scientific Research (FNRS, Crédit au chercheur 1.5303.04) and from UPSA (Institut de la douleur). EH is the Research Director of the FNRS.

Conflict of interest

The authors state no conflict of interest.

References

Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. *Br J Pharmacol* 153 (Suppl 2): S1–S209.

- Bash R, Rubovitch V, Gafni M, Sarne Y (2003). The stimulatory effect of cannabinoids on calcium uptake is mediated by G_s GTP-binding proteins and cAMP formation. *Neurosignals* 12: 39–44.
- Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. *J Pharmacol Exp Ther* 287: 884–888.
- Bosier B, Hermans E (2007). Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. *Trends Pharmacol Sci* 28: 438–446.
- Bosier B, Tilleux S, Najimi M, Lambert DM, Hermans E (2007). Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. *J Neurochem* 102: 1996–2007.
- Bouaboula M, Pointot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M *et al.* (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB₁. *Biochem J* 312 (Part 2): 637–641.
- Calandra B, Portier M, Kerneis A, Delpech M, Carillon C, Le Fur G *et al.* (1999). Dual intracellular signaling pathways mediated by the human cannabinoid CB₁ receptor. *Eur J Pharmacol* 374: 445–455.
- Casu MA, Pisu C, Sanna A, Tambaro S, Spada GP, Mongeau R *et al.* (2005). Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study. *Brain Res* 1048: 41–47.
- Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996). Cannabinoid inhibition of adenylyl cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. *J Biol Chem* 271: 13175–13183.
- Faubert BL, Kaminski NE (2000). AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. *J Leukoc Biol* 67: 259–266.
- Giuliano M, Calvaruso G, Pellerito O, Portanova P, Carlisi D, Vento R *et al.* (2006). Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. *Int J Mol Med* 17: 811–819.
- Glass M, Felder CC (1997). Concurrent stimulation of cannabinoid CB₁ and dopamine D₂ receptors augments cAMP accumulation in striatal neurons: evidence for a G_s linkage to the CB₁ receptor. *J Neurosci* 17: 5327–5333.
- Glass M, Northup JK (1999). Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. *Mol Pharmacol* 56: 1362–1369.
- Hampson RE, Mu J, Deadwyler SA (2000). Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. *J Neurophysiol* 84: 2356–2364.
- Herring AC, Faubert Kaplan BL, Kaminski NE (2001). Modulation of CREB and NF-kappaB signal transduction by cannabinol in activated thymocytes. *Cell Signal* 13: 241–250.
- Herring AC, Koh WS, Kaminski NE (1998). Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. *Biochem Pharmacol* 55: 1013–1023.
- Ho BY, Uezono Y, Takada S, Takase I, Izumi F (1999). Coupling of the expressed cannabinoid CB₁ and CB₂ receptors to phospholipase C and G protein-coupled inwardly rectifying K⁺ channels. *Receptors Channels* 6: 363–374.
- Jarrahian A, Watts VJ, Barker EL (2004). D₂ dopamine receptors modulate G_α-subunit coupling of the CB₁ cannabinoid receptor. *J Pharmacol Exp Ther* 308: 880–886.
- Kim KS, Park DH, Wessel TC, Song B, Wagner JA, Joh TH (1993). A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression. *Proc Natl Acad Sci USA* 90: 3471–3475.
- Koh WS, Crawford RB, Kaminski NE (1997). Inhibition of protein kinase A and cyclic AMP response element (CRE)-specific transcription factor binding by delta9-tetrahydrocannabinol (delta9-THC): a putative mechanism of cannabinoid-induced immune modulation. *Biochem Pharmacol* 53: 1477–1484.
- Lauckner JE, Hille B, Mackie K (2005). The cannabinoid agonist WIN55212-2 increases intracellular calcium via CB₁ receptor

- coupling to Gq/11 G proteins. *Proc Natl Acad Sci USA* **102**: 19144–19149.
- Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM (2004). Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. *Mol Cell Neurosci* **25**: 536–547.
- Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A *et al.* (2003). The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. *J Biol Chem* **278**: 33896–33903.
- Mackie K, Hille B (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. *Proc Natl Acad Sci USA* **89**: 3825–3829.
- Mackie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci* **15**: 6552–6561.
- Maneuf YP, Brotchie JM (1997). Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. *Br J Pharmacol* **120**: 1397–1398.
- McIntosh BT, Hudson B, Yegorova S, Jollimore CA, Kelly ME (2007). Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. *Br J Pharmacol* **152**: 1111–1120.
- Mukhopadhyay S, Howlett AC (2005). Chemically distinct ligands promote differential CB1 cannabinoid receptor-G_i protein interactions. *Mol Pharmacol* **67**: 2016–2024.
- Murphy MG, Byczko Z (1989). Effects of adenosine analogues on basal, prostaglandin E₁- and forskolin-stimulated cyclic AMP formation in intact neuroblastoma cells. *Biochem Pharmacol* **38**: 3289–3295.
- Najimi M, Robert JJ, Mallet J, Rostene W, Forgez P (2002). Neurotensin induces tyrosine hydroxylase gene activation through nitric oxide and protein kinase C signaling pathways. *Mol Pharmacol* **62**: 647–653.
- Ouyang Y, Hwang SG, Han SH, Kaminski NE (1998). Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonoyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. *Mol Pharmacol* **53**: 676–683.
- Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. *Curr Med Chem* **6**: 635–664.
- Pierreux CE, Urso B, De Meyts P, Rousseau GG, Lemaigre FP (1998). Inhibition by insulin of glucocorticoid-induced gene transcription: involvement of the ligand-binding domain of the glucocorticoid receptor and independence from the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. *Mol Endocrinol* **12**: 1343–1354.
- Porcella A, Gessa GL, Pani L (1998). Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. *Eur J Neurosci* **10**: 1743–1751.
- Prather PL, Martin NA, Breivogel CS, Childers SR (2000). Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. *Mol Pharmacol* **57**: 1000–1010.
- Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V *et al.* (2007). Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. *Neuropharmacology* **32**: 2036–2045.
- Rubovitch V, Gafni M, Sarne Y (2002). The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. *Brain Res Mol Brain Res* **101**: 93–102.
- Rueda D, Galve-Roperh I, Haro A, Guzman M (2000). The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. *Mol Pharmacol* **58**: 814–820.
- Stenstrom S, Seppala M, Pfenning M, Richelson E (1985). Inhibition by ethanol of forskolin-stimulated adenylate cyclase in a murine neuroblastoma clone (N1E-115). *Biochem Pharmacol* **34**: 3655–3659.
- Sugiura T, Kodaka T, Kondo S, Nakane S, Kondo H, Waku K *et al.* (1997). Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca²⁺ transient in NG108-15 cells. *J Biochem (Tokyo)* **122**: 890–895.
- Sugiura T, Kodaka T, Kondo S, Toneyawa T, Nakane S, Kishimoto S *et al.* (1996). 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca²⁺ in neuroblastoma × glioma hybrid NG108-15 cells. *Biochem Biophys Res Commun* **229**: 58–64.
- Zhao Q, He Z, Chen N, Cho YY, Zhu F, Lu C *et al.* (2005). 2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells. *J Biol Chem* **280**: 26735–26742.